Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection
Authors:
- Grenville ThynneGTGrenville Thynne
- Paul MitchellPMPaul Mitchell
- Chin-Swee OngCOChin-Swee Ong
- Dishan GunawardanaDGDishan Gunawardana
- Robert BlumRBRobert Blum
- Julian PearsonJPJulian Pearson
- Jodie LoddingJLJodie Lodding
- Geoff PieterszGPGeoff Pietersz
- Russell BroadbentRBRussell Broadbent
- Brian TaitBTBrian Tait
- Ian F. C. McKenzieIMIan F. C. McKenzie
- 1 March 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 24 (2) , 172-183
Abstract
The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUC1 conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses. On this basis, three phase I trials were performed in patients with adenocarcinoma to evaluate the tnxicity and the immunologic responses to mannan MUC1. Forty-one patients with metastatic or locally advanced carcinoma of the breast (trial 1), colon (trial 2), and various adenocarcinomas (trial 3) received increasing doses of M-FP (1 to 300 μg). The immunizations were given at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide (to increase cellular immunity) was given on weeks 1 and 4. M-FP was given intramuscularly in trial 1 and intraperitoneally in trial 2. No toxic effects occurred, and delayed-type hypersensitivity responses were present only as a microscopic lymphocytic infiltration. Overall, approximately 60% of the patients had high-titer MUC1 immunoglobulin G1 antibody responses, with the intraperitoneal route yielding approximately 10-fold higher responses. Cellular responses (proliferation, cytotoxic T cells, or CD8 T cells secreting tumor necrosis factor-α αnd interferon-γ in response to MUC1 stimulation in vitro) were found in 28% of the patients, which was similar to that seen without cyclophosphamide. In most patients, disease progressed, but in five it remained stable. In addition, there were no objective responses. M-FP is not toxic and induces immune responses that were amplified by the intraperitoneal route of immunization. Cyclophosphamide was of no benefit.Keywords
This publication has 16 references indexed in Scilit:
- MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoralNature Medicine, 1998
- Cyclophosphamide Enhances the CTL Precursor Frequency in Mice Imrnunized with MUC1-Mannan Fusion Protein (M-FP)Journal of Immunotherapy, 1998
- Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.Journal of Clinical Investigation, 1997
- A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancerBritish Journal of Cancer, 1996
- A Phase I Trial of a Synthetic Mucin Peptide VaccineJournal of Surgical Research, 1996
- Cell-mediated immune responses to MUC1 fusion protein coupled to mannanVaccine, 1996
- Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn VaccineJournal of Immunotherapy, 1996
- Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.Proceedings of the National Academy of Sciences, 1995
- Epithelial Mucin GenesAnnual Review of Physiology, 1995
- Immune Modulating Effects of Low Doses of Cyclophosphamide and Keyhole Limpet Hemocyanine on Peripheral Blood Immune Parameters in Patients with Metastatic Renal Cell CarcinomaUrologia Internationalis, 1992